RxDoctor Payments Data

Hani Seifein, MD

Interventional Cardiology · Orlando, FLNPI 1942207055

Payments from drug & device makers

$18,910in general payments, 2019–2025

Across 67 payments — averaging $282.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$8K
  • Amarin Pharma, Inc.$7K
  • Sanofi-aventis U.S. LLC$950
  • Cvrx, Inc.$492
  • Abiomed$410
  • Novo Nordisk$347
  • plus $2K from 12 others

What the payments were for

  • Consulting fees$250%
  • Speaking & faculty fees$6,95037%
  • Travel & lodging$5,38728%
  • Food & beverage$6,50634%
  • Education$420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,910 in reported general payments places this provider in the 65th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$246,461
Medicare patients
3,452
Services billed
6,221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban179$194,816
VascepaIcosapent Ethyl107$74,596
Repatha SureclickEvolocumab71$62,890
JardianceEmpagliflozin43$53,958
EntrestoSacubitril/Valsartan32$41,987
BrilintaTicagrelor40$38,255
Praluent PenAlirocumab28$19,395
Icosapent Ethyl28$9,974
Ezetimibe384$7,054
Rosuvastatin Calcium443$4,925
Atorvastatin Calcium334$2,804
Amlodipine Besylate475$2,646
Hydralazine Hcl159$2,421
Carvedilol291$2,193
ClopidogrelClopidogrel Bisulfate181$2,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$124$194,816179 claims
Boehringer IngelheimJardiance$117$53,95843 claims
NovartisEntresto$266$41,98732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →